2025 Review Finds a Key Gap in Ketamine Research: Suicidal Behavior Outcomes

A systematic review published in Translational Psychiatry on February 6, 2025, identified an important boundary in recent ketamine research: studies reporting changes in suicidal thoughts should not be treated as direct proof of suicide prevention. None of the trials included in the review had suicidal behavior as an outcome. Read the review and its outcome assessment.

What the researchers examined

Sumra Sajid, J. John Mann, and Michael F. Grunebaum reviewed clinical trials since 2020 involving ketamine or its enantiomers and clinically significant suicidal ideation or behavior. Fourteen randomized controlled trials met the review criteria. The authors also included two open-label R-ketamine trials because published evidence for that formulation was limited. The abstract outlines the selection process.

That distinction between randomized and open-label evidence matters. In an open-label study, participants and investigators know the treatment being given. Such findings should not be presented as carrying the same safeguards against expectation effects as a blinded randomized comparison.

A varied set of interventions

The reviewed research covered different routes of administration, including intravenous, intramuscular, and intranasal approaches. It also included single-dose and repeated-dose designs and studies in which ketamine augmented another treatment, such as electroconvulsive therapy. The review describes the range of trial designs.

These were not interchangeable versions of one standardized intervention. Differences in formulation, treatment schedule, population, and accompanying care limit how confidently one study’s findings can be transferred to another service or product.

What the findings suggested

The authors reported that repeated intravenous ketamine or S-ketamine produced reductions in suicidal ideation lasting several days to weeks in reviewed trials. Single-dose effects were shorter or more variable, and intranasal ketamine or S-ketamine findings were less consistent. Read the results summary.

The result is more nuanced than a universal claim that ketamine rapidly eliminates suicidality. Some approaches showed encouraging symptom effects, but the review did not find one uniform outcome across every route and dosing pattern.

The central evidence gap

The reviewed trials assessed suicidal ideation, not suicidal behavior as an outcome. This means their findings cannot directly establish a reduction in attempts or deaths. It is an outcome-measure limitation, not merely a dispute about whether symptom improvement is meaningful. The authors explicitly identify this gap.

For medical reporting, the implication is straightforward: state the measured outcome. A reduction on a suicidal-thought scale should be described as such, without replacing it with broader language about preventing suicide.

How the review fits with Spravato labeling

Spravato’s U.S. label allows treatment of depressive symptoms in adults with major depressive disorder and acute suicidal ideation or behavior when used with an oral antidepressant. The same label states that effectiveness in preventing suicide or reducing suicidal ideation or behavior has not been demonstrated. Read the indication and limitations together.

The label also says improvement after an initial dose does not remove the need for hospitalization when clinically warranted. This is an important boundary for interpreting reports of fast symptom relief during a psychiatric crisis.

What this changes for readers

Patients, families, and clinicians evaluating a headline can ask three questions: what outcome was measured, how long was it followed, and which exact treatment was used? If those details are missing, a strong-sounding claim may conceal a much narrower finding.

• Suicidal thoughts and suicidal behavior are distinct outcomes.
• Single-dose and repeated-dose findings should not be conflated.
• Evidence from one route should not automatically be assigned to another.
• Open-label findings should be identified as preliminary.

The review supports continued investigation of rapid changes in suicidal ideation while making the limits of that evidence visible. It does not justify abandoning crisis assessment, follow-up, or other necessary care.

Anyone facing imminent danger or unable to remain safe should seek emergency help immediately rather than waiting for a ketamine-related appointment.

Sources

• Translational Psychiatry: Clinical trials since 2020 systematic review
• PubMed: Review abstract
• FDA: Spravato limitations of use